High-level results from the randomized, controlled NHS-Galleri trial, which is evaluating GRAIL’s multi-cancer screening test, Galleri, over three years in 142,000 participants aged 50 to 77, reveals that the trial did not meet its primary endpoint of shifting cancer diagnosis from advanced stages (3 and 4) to earlier stage (1 and 2).
Diaceutics has released research revealing a critical shift in precision medicine. Despite major advances in biomarker testing, nearly two-thirds of eligible patients with advanced non-small cell lung cancer in the U.S. are still not receiving the most appropriate treatment.
